BCC Stock Recent News

Volatility is back, and while it's normal, fear dominates. Investors are uneasy despite no official correction, as past gains spoiled expectations. Economic uncertainty, rising debt, and inflation risks fuel market anxiety. If Trump acts on lower rates, short-term pain may be inevitable. I'm seizing opportunities, focusing on value and cyclical dividend growth. Buying dips has historically paid off, and I'm betting big on key stocks.

The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies with strong fundamentals. I focus on businesses with resilient models, growth potential, and attractive valuations. Despite headline risks, I believe in their ability to navigate uncertainty and deliver long-term returns. While risks like prolonged trade tensions or economic slowdowns exist, I remain confident in my picks, as they are well-positioned to thrive regardless of short-term market turbulence.

Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.

The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) Percent

The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin.

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE

BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (Boise Cascade) (NYSE: BCC) announced today that Nathan Sikes will be the new Senior Vice President of Western Operations for their Building Materials Distribution (BMD) division, effective February 24, 2025. In this role, Nathan will be responsible for BMD's facilities and door shops located in the Western and Pacific Regions. Since joining Boise Cascade in 2006, Nathan has held a series of key roles and progressive leadership positions in t.

Boise Cascade Company, Inc. (NYSE:BCC ) Q4 2024 Earnings Conference Call February 21, 2025 11:00 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Conference Call Participants Kurt Yinger - D.A. Davidson Susan Maklari - Goldman Sachs Mike Roxland - Truist Securities George Staphos - Bank of America Merrill Lynch Ketan Mamtora - BMO Capital Markets Operator Good morning.